Rasmussen K, Wang H, Fausa D
Acta Med Scand Suppl. 1981;645:23-8. doi: 10.1111/j.0954-6820.1981.tb02597.x.
Fifty-three patients with chronic atrial fibrillation participated in a randomized cross-over trial in order to compare the ability of two drug regimens to establish and maintain sinus rhythm. The patients were given orally either sustained release quinidine 0.4 g twice day or verapamil 80 mg three times a day. Thirty-one patients tried both regimens. Quinidine was found to have a greater ability to induce conversion to sinus rhythm by drug alone (p less than 0.05) and also a greater ability to maintain sinus rhythm after conversion (after 3 months p less than 0.05). There was, however, also a significantly larger proportion of patients on quinidine who were withdrawn from the study due to side effects and two patients on quinidine died outside hospital. The study indicate that quinidine is somewhat superior to verapamil both in the establishing and preserving of sinus rhythm in subjects who are able to tolerate the drug.
53名慢性房颤患者参与了一项随机交叉试验,以比较两种药物疗法建立并维持窦性心律的能力。患者口服缓释奎尼丁,每日两次,每次0.4克,或维拉帕米,每日三次,每次80毫克。31名患者尝试了两种疗法。结果发现,仅使用药物时,奎尼丁诱导转为窦性心律的能力更强(p<0.05),且转为窦性心律后维持窦性心律的能力也更强(3个月后,p<0.05)。然而,服用奎尼丁的患者中,因副作用退出研究的比例也显著更高,且有两名服用奎尼丁的患者在院外死亡。该研究表明,在能够耐受药物的受试者中,奎尼丁在建立和维持窦性心律方面略优于维拉帕米。